Key result
DAPT after DES in cirrhosis precipitates fatal recurrent gastrointestinal bleeding and hepatorenal syndrome.
Why the study?
New developments in drug-eluting stents and optimal dual antiplatelet therapy duration may further limit bare-metal stent use, while dual antiplatelet therapy after PCI is complicated in patients with cirrhosis and potential coagulopathy.
Case Report (n=1)
No
This case report and literature review highlights the severe bleeding risks of dual antiplatelet therapy after drug-eluting stent placement in patients with cirrhosis and underscores the lack of trial evidence guiding optimal stent selection and DAPT duration in end-stage liver disease.
Answers are grounded in this paper and cite their sources.
Case highlights bleeding risk with DAPT post-DES in cirrhosis; leaves open optimal stent selection and DAPT duration in end-stage liver disease.
Drug-eluting stents (DES) have superior efficacy compared with bare metal stents (BMS) for treatment of coronary artery lesions. However, BMS continue to play an important role in percutaneous coronary intervention for patients who are at a high bleeding risk, because they require a shorter duration of dual antiplatelet therapy. However, new developments in DES and understanding of the optimal time required for dual antiplatelet therapy after percutaneous coronary intervention may further limit the use of BMS. Furthermore, the use of dual antiplatelet therapy is complicated in patients with cirrhosis, who may have coagulopathy. In this article, we present the case of a patient with cirrhosis and end-stage chronic liver disease with coronary artery disease and a proximal left anterior descending stenosis who received a DES and had multiple episodes of gastrointestinal bleeding. We review the literature addressing DES and BMS in patients at high risk of bleeding. We also review the optimal duration of dual antiplatelet therapy.
No takes yet. Share an insight, caveat, or question.
Remillard et al. (2021) conducted a case report in Coronary artery disease (>95% proximal LAD stenosis) and decompensated alcoholic cirrhosis with high bleeding risk (n=1). Percutaneous coronary intervention with drug-eluting stent (everolimus-eluting stent) and dual antiplatelet therapy (aspirin and clopidogrel) was evaluated on Recurrent gastrointestinal bleeding and clinical decompensation. Dual antiplatelet therapy after drug-eluting stent placement in a 69-year-old man with cirrhosis led to recurrent gastrointestinal bleeding, hepatorenal syndrome, and death.
Synapse has enriched 10 related papers. Consider them for comparative context: